anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The first embodiment of the present invention provides a composition, which includes:at least one aqueous phase that includes an aqueous suspension of particles of an at least partially crosslinked organopolysiloxane elastomer; andat least one sugar or sugar derivative. Other embodiments of the invention provide for the use of the above-described composition. Another embodiment of the invention provides a method selected from the group including treating, protecting, caring for, removing make-up from, and cleaning at least one selected from the group including the skin, lips and hair, and combinations thereof, which method includes applying the above-described composition to the skin, lips or hair. Another embodiment of the invention provides a method for treating or caring for at least one selected from the group including dry skin, dry lips, sensitive skin, and combinations thereof which includes applying to at least one selected from the group including dry skin, dry lips, sensitive skin, and combinations thereof in need thereof the above-described composition. Another embodiment of the invention provides a method for preparing an emulsion composition, which method includes separately heating an oily phase and an aqueous phase, the aqueous phase including an aqueous suspension of particles of an at least partially crosslinked organopolysiloxane elastomer and at least one sugar or sugar derivative, to obtain a heated oily phase and a heated aqueous phase; admixing the heated oily phase and the heated aqueous phase and emulsifying, to obtain the emulsion composition. Another embodiment of the invention provides a method for reducing or eliminating the sticky feel of a composition that includes at least one sugar or sugar derivative, which method includes introducing into the composition an aqueous suspension of particles of an at least partially crosslinked organopolysiloxane elastomer.
PURPOSE:To simplify an operation and to shorten time for manufacturing the title seal by heating and softening the title seal material with polyester acetic propionic cellulose as its substantial component, creating a model from the obtained seal, and shifting the model to an engagement seal as a personal tray. CONSTITUTION:The seal material is polyester acetic propionic cellulose, and a fine particle having an approximately 150mu dimension is obtained by freezing and finely grinding the material. A heater 18 is a device in which heating plates 19a and 19b respectively having conductive heating members in them are opposed to each other and opened or closed with a hinge 21 as the center of the opening and closing action, and the heater 18 can rise the temperature of itself up to its maximum temperature 105 deg.C so that the heater 18 can immediately heat the seal material up to 72-82 deg.C. In order to select a tray 20, measurement is executed using a divider, etc., the necessary amount of seal material 27 is placed in the heater 18, the heating plates 19a and 19b are closed, and the seal material 27 is dried and heated. The seal material composed of the fine particles is melted and unified by the heating. The unified seal material is positioned in the tray 20. Since the seal material is not hardened yet even after the positioning of the seal material ends, the above-mentioned process is shifted to the next process. The tray is inserted into an oral cavity and press-welded to a prescribed position.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. 

A total of 359 patients with neuropathic pain associated with postherpetic neuralgia have received gabapentin tablets at doses up to 1,800 mg daily during placebo-controlled clinical studies. In clinical trials in patients with postherpetic neuralgia, 9.7% of the 359 patients treated with gabapentin tablets and 6.9% of 364 patients treated with placebo discontinued prematurely due to adverse reactions. In the gabapentin tablets treatment group, the most common reason for discontinuation due to adverse reactions was dizziness. Of gabapentin tablets-treated patients who experienced adverse reactions in clinical studies, the majority of those adverse reactions were either "mild" or "moderate”. 

Table 4 lists all adverse reactions, regardless of causality, occurring in at least 1% of patients with neuropathic pain associated with postherpetic neuralgia in the gabapentin tablets group for which the incidence was greater than in the placebo group.

Table 4: Treatment-Emergent Adverse Reaction Incidence in Controlled Trials in Neuropathic Pain Associated with Postherpetic Neuralgia (Events in at Least 1% of all Gabapentin Tablets-Treated Patients and More Frequent Than in the Placebo Group)

In addition to the adverse reactions reported in Table 4 above, the following adverse reactions with an uncertain relationship to gabapentin tablets were reported during the clinical development for the treatment of postherpetic neuralgia. Events in more than 1% of patients but equally or more frequently in the gabapentin tablets-treated patients than in the placebo group included blood pressure increase, confusional state, gastroenteritis viral, herpes zoster, hypertension, joint swelling, memory impairment, nausea, pneumonia, pyrexia, rash, seasonal allergy, and upper respiratory infection.
The process of aging involves numerous structural and functional changes also affecting the skin. The skin fulfills a variety of protective and regulatory functions. Compared to other organs, the skin is constantly exposed to harmful environmental influences. Besides intrinsic factors these external factors may accelerate skin aging. Due to its ageing-related loss of functional capacity the skin becomes susceptible to develop adverse skin conditions and dermatological diseases (e.g. skin dryness, fungal infections). Especially old aged, care depended, and severely ill individuals are at high risk for developing severe skin injuries and wounds (e.g. decubitus, skin tears) with high social and economic impact. Empirical evidence indicates that the reduced adhesion of the dermal-epidermal junction is a major pathophysiological predictor for these types of injuries.

The suction blister model is an artificial and controlled technique for dermal-epidermal separation along the dermo-epidermal junction (DEJ). Empirical evidence suggests that the time of the dermal-epidermal separation (blistering time) is a measure of the dermo-epidermal adhesion. It has been proposed that the blistering time might be a clinically relevant parameter reflecting the mechanical integrity/stability of the dermo-epidermal junction.

Clinical practice guidelines recommend the use of topical skin care products to reduce the risk for pressure ulcer and skin tear development. However, the underlying working mechanisms of most basic skin care products are poorly understood. It is known that topically applied skin care products exhibit physical and chemical effects on and in the uppermost skin layers (e.g. the stratum corneum). Despite a few well known active ingredients (e.g. retinoids, vitamin C) exhibiting effects in the dermis, a particular skin protective effect of the vast majority of daily basic skin care applications on these deeper skin layers is unknown. The primary objective of this study is to test, whether the use of a basic skin care formulation increases the mechanical integrity/adhesion of the dermo-epidermal junction.
This will be a crossover study with 2 cohorts and an interleaving design with placebo substitution. The study will be conducted over 4 treatment periods in Cohort 1 (n=9) and over 3 treatment periods in Cohort 2 (n=9). Six subjects will be allocated to receive PF-04991532 and three subjects will be allocated to receive placebo treatment during each dosing period, except for the 4th period of Cohort 1. The 4th period of Cohort 1 will be dedicated to assess the effect of food on PF-04991532 PK parameters at one of the doses previously tested in Cohort 1; hence all 9 subjects will be dosed with PF-04991532 in an open-label fashion. A washout period of at least 7 days will occur between each dose.
The investigators utilize a pragmatic randomized controlled trial design to evaluate the effectiveness of dietary intervention in real-world conditions, without strict control, thereby enhancing the generalizability and clinical applicability of our study findings. Participants at Shenzhen Third People's Hospital, exhibiting HIV with CVD risk will be enrolled. Upon providing informed consent, participants will undergo dynamic randomization into intervention and control groups, aiming for a 1:1 ratio while preserving maximum unpredictability. The intervention group will receive the gut microbiota-targeted dietary intervention thrice weekly for 3 months, accompanied by bi-weekly healthy diet guidance for the same duration. Meanwhile, the control group will continue routine follow-up and health education practices. The intervention will span three months, followed by a three-month follow-up period. Data collection will occur at baseline, 3 months, and 6 months. Primary outcomes will assess ASCVD risk via the pooled cohort equation and evaluate gut microbiota diversity and composition. Secondary outcomes will encompass biomarkers and predictors associated with atherosclerotic cardiovascular disease, as well as symptoms related to the condition.
The olfactory epithelium (OE) is directly exposed to environmental agents entering the nasal cavity, leaving OSNs prone to injury and degeneration. The causes of olfactory dysfunction are diverse and include head trauma, neurodegenerative diseases, and aging, but the main causes are chronic rhinosinusitis (CRS) and viral infections. In CRS and viral infections, reduced airflow due to local inflammation, inflammatory cytokine production, release of degranulated proteins from eosinophils, and cell injury lead to decreased olfactory function. It is well known that injury-induced loss of mature OSNs in the adult OE causes massive regeneration of new OSNs within a few months through the proliferation and differentiation of progenitor basal cells that are subsequently incorporated into olfactory neural circuits. Although normal olfactory function returns after injury in most cases, prolonged olfactory impairment and lack of improvement in olfactory function in some cases poses a major clinical problem. Persistent inflammation or severe injury in the OE results in morphological changes in the OE and respiratory epithelium and decreases the number of mature OSNs, resulting in irreversible loss of olfactory function. In this review, we discuss the histological structure and distribution of the human OE, and the pathogenesis of olfactory dysfunction associated with CRS and viral infection.
STUDY DESIGN: Retrospective analysis of prospectively enrolled patients.
OBJECTIVE: To evaluate the relationship between paraspinal muscle (PM) atrophy and Oswestry Disability Index (ODI) improvement after spinal fusion surgery for degenerative lumbar spondylolisthesis.
BACKGROUND: Atrophy of the PM is linked to multiple spinal conditions, sagittal malalignment, and increased postoperative complications. However, only limited evidence for the effect on patient-reported outcomes exists.
METHODS: Patients with degenerative lumbar spondylolisthesis undergoing decompression and fusion surgery were analyzed. Patients with missing follow-up, no imaging, or inadequate image quality were excluded. The ODI was assessed preoperatively and two years postoperatively. A cross-sectional area of the PM was measured on a T2-weighted magnetic resonance imaging sequence at the upper endplate of L4. On the basis of the literature, a 10-point improvement cutoff was defined as the minimum clinically important difference. Patients with a baseline ODI below the minimum clinically important difference were excluded. Logistic regression was used to calculate the association between fatty infiltration (FI) of the PM and improvement in ODI, adjusted for age, sex, and body mass index.
RESULTS: A total of 133 patients were included in the final analysis, with only two lost to follow-up. The median age was 68 years (IQR 62-73). The median preoperative ODI was 23 (IQR 17-28), and 76.7% of patients showed improvement in their ODI score by at least 10 points. In the multivariable regression, FI of the erector spinae and multifidus increased the risk of not achieving clinically relevant ODI improvement ( P =0.01 and <0.001, respectively). No significant association was found for the psoas muscle ( P =0.158).
CONCLUSIONS: This study demonstrates that FI of the erector spinae and multifidus is significantly associated with less likelihood of clinically relevant ODI improvement after decompression and fusion. Further research is needed to assess the effect of interventions.
NEW MATERIAL:1-Deoxynojirimycin derivative of formula I (R is H, halogen, lower alkyl, lower alkoxy; n is 0, 1-5). EXAMPLE:N-Phenethylcarbamoyl-1-deoxynojirimycin. USE:It has hypolipemic action and is used as a preventive or remedy for hyperlipemia, arteriosclerosis and a variety of diseases caused thereby. It is low in toxicity and can be given orally. PREPARATION:1-Deoxynojirimycin of formula II is dispersed in an organic solvent, preferably in dimethylformamide. Then, a substituted aralkyl isocyanate of formula III is added and they are stirred. After the completion of the reaction, the organic solvent is distilled off to obtain the compound of formula I. The compound of formula II is obtained from nojirimycin (5-amino-5-deoxy-D-glycopyranose) of formula IV.
IMPOYZ Cream can cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency. This may occur during treatment or after withdrawal of treatment. Because of the potential for systemic absorption, use of topical corticosteroids, including IMPOYZ Cream, may require that patients be evaluated periodically for evidence of HPA axis suppression. Factors that predispose a patient to HPA axis suppression include the use of high-potency steroids, large treatment surface areas, prolonged use, use of occlusive dressings, altered skin barrier, liver failure, and young age.

Evaluation for HPA axis suppression may be done by using the adrenocorticotropic hormone (ACTH) stimulation test. In a trial evaluating the effects of IMPOYZ Cream on the HPA axis, subjects with plaque psoriasis applied IMPOYZ Cream twice daily to at least 20% of involved Body Surface Area (BSA) for 15 days. Abnormal ACTH stimulation tests suggestive of HPA axis suppression were seen in 3 of 24 (12.5%) subjects on IMPOYZ Cream [see Clinical Pharmacology (12.2)]. In another trial to evaluate the effects of IMPOYZ Cream on the HPA axis, subjects with moderate to severe plaque psoriasis applied IMPOYZ Cream twice daily to at least 25% of involved BSA for 28 consecutive days. Abnormal ACTH stimulation test suggestive of HPA axis suppression was seen in 8 of 26 (30.8%) of subjects on IMPOYZ Cream.

If HPA axis suppression is documented, gradually withdraw the drug, reduce the frequency of application, or substitute with a less potent corticosteroid. If signs and symptoms of steroid withdrawal occur, supplemental systemic corticosteroids may be required. Recovery of HPA axis function is generally prompt and complete upon discontinuation of topical corticosteroids.

Systemic effects of topical corticosteroids may also manifest as Cushing’s syndrome, hyperglycemia, and glucosuria. These complications are rare and generally occur after prolonged exposure to larger than recommended doses, particularly with high-potency topical corticosteroids. 

Use of more than one corticosteroid-containing product at the same time may increase the total systemic exposure to topical corticosteroids.

Minimize the unwanted risks from endocrine effects by mitigating risk factors favoring increased systemic bioavailability and by using the product as recommended [see Dosage and Administration (2)].

Pediatric patients may be more susceptible to systemic toxicity because of their larger skin surface to body mass ratios [see Use in Specific Populations (8.4)].
COPD is an inflammatory lung disease that limits airflow and remodels the pulmonary vascular system. This study delves into the therapeutic potential and mechanistic underpinnings of Panax notoginseng Saponins (PNS) in alleviating inflammation and pulmonary vascular remodeling in a COPD rat model. Symmap and ETCM databases provided Panax notoginseng-related target genes, and the CTD and DisGeNET databases provided COPD-related genes. Intersection genes were subjected to protein-protein interaction analysis and pathway enrichment to identify downstream pathways. A COPD rat model was established, with groups receiving varying doses of PNS and a Roxithromycin control. The pathological changes in lung tissue and vasculature were examined using histological staining, while molecular alterations were explored through ELISA, RT-PCR, and Western blot. Network pharmacology research suggested PNS may affect the TLR4/NF-κB pathway linked to COPD development. The study revealed that, in contrast to the control group, the COPD model exhibited a significant increase in inflammatory markers and pathway components such as TLR4, NF-κB, HIF-1α, VEGF, ICAM-1, SELE mRNA, and serum TNF-α, IL-8, and IL-1β. Treatment with PNS notably decreased these markers and mitigated inflammation around the bronchi and vessels. Taken together, the study underscores the potential of PNS in reducing lung inflammation and vascular remodeling in COPD rats, primarily via modulation of the TLR4/NF-κB/HIF-1α/VEGF pathway. This research offers valuable insights for developing new therapeutic strategies for managing and preventing COPD.
PROBLEM TO BE SOLVED: To obtain an insoluble fraction having protecting effects on hepatic dysfunction without adverse effects, usable with administration of a drug causing the hepatic dysfunction and excellent in safety by treating an extract from a mycelium of Lentinus edodes Sing. with a solution containing ethanol. SOLUTION: This fractionated substance is obtained by treatment of an extract from a mycelium of Lentinus edodes Sing. with a solution containing ethanol. Furthermore, the insoluble fraction is preferably formulated with a pharmaceutically acceptable carrier as an optional ingredient to prepare a therapeutic and/or a prophylatic composition for hepatopathy. The protecting agent for the hepatopathy is for oral use and useful for foods and beverages. The daily dose of the ethanol-insoluble fraction is preferably within the range of 80-360 mg.
Volume controlled ventilation: tidal volume of 7 mL/kg ideal body weight, frequency of 12 cycles/minute, I/E ratio of 1:2, no positive end expiratory pressure. Ventilatory frequency is changed if necessary to maintain end-expiratory pressure of CO2 between 35 and 40 mmHg.
The present invention relates to a multi-layer stainless steel cylinder head (MLS) gasket that includes a unitary sealant layer interposed between the outer layers chamfered in mirror image. A sealing ring placed around the boundary of a combustion opening in the sealing layer is formed by refolding the edge of the sealing layer material boundary. The sealing ring pre-tensiones the packing interface around the combustion opening during the securing of a cylinder head to a motor block. The sealing layer includes at least one high epoxy ridge structure circumferentially and closely surrounding the outer edge of the sealing ring. The epoxy flange acts to distribute the load and therefore avoid concentrated loads at the boundary of the combustion opening. The epoxy flange is applied to the stencil packing and can incorporate a powder metal to limit the elasticity of the flange. The height of the flange is greater than the thickness of the sealing ring to reduce the risk of splitting of the sealed layer material
PURPOSE OF REVIEW: In 2017, the American Joint Committee on Cancer (AJCC) introduced the inclusion of extracapsular nodal extension (ENE) into the N staging of nonviral head and neck squamous cell carcinoma (HNSCC), while retaining the traditional N classification based on the number and sizes of metastatic nodes. The extent of ENE was further defined as microscopic ENE (ENEmi) and major ENE (ENEma) based on extent of disease beyond the nodal capsule (≤ or > 2 mm). This article reviews the evidence and progress made since these changes were introduced.
RECENT FINDINGS: The 'gold standard' for evaluation ENE is histopathologic examination, the current preferred primary treatment of patients with HNSCC is by radiation-based therapy ± chemotherapy or biotherapy. The current pretreatment staging is by imaging, which needs improved reliability of radiologic rENE assessment with reporting needs to consider both sensitivity and specificity (currently computed tomography images have high-specificity but low-sensitivity). Adjuvant chemotherapy is indicated for patients with ENEma to enhance disease control, whereas for patients with ENEmi, there is a need to assess the benefit of adjuvant chemotherapy. Evidence that the presence of pENE in HPV-positive oropharyngeal carcinoma is an independent prognostic factor and should be considered for inclusion in future AJCC editions has recently emerged.
SUMMARY: There remains a paucity of data on the reliability of imaging in the staging of rENE, more so the for the accurate assessment of ENEmi. Optimistic early results from use of artificial intelligence/deep learning demonstrate progress and may pave the way for better capabilities in tumor staging, treatment outcome prediction, resulting in improved survival outcomes.
The 0.005% sodium hypochlorite solutions will be prepared from the commercially available Clorox® at 6% solution. 0.83ml of the 6% sodium hypochlorite solution will be taken and incorporated to a-100ml absolute distilled water.
A single pass, continuous, automated system for producing a pharmaceutical granulation includes multiple feeders to feed powders and liquids, a twin screw processor to granulate, a radio frequency or microwave based drying apparatus to dry the granulation, and at least one mill to process the dried granulation to desired particle sizes. The system incorporates means for monitoring key process parameters on-line. The granulation produced can be compressed into a tablet or incorporated into a capsule, both having a uniform distribution of the active ingredient. The system produces product having consistent properties even when production is scaled up for manufacture of the tablet in commercial volume. A single pass, continuous, automated system for producing a high dose pharmaceutical granulation from a low density active ingredient, includes multiple feeders to feed powders and liquids, a twin screw processor to granulate, a radio frequency or microwave based drying apparatus to dry the granulation, and at least one mill to process the dried granulation to desired particle sizes. The system produces product having consistent properties even when production is scaled up for manufacture of the tablet in commercial volume. The twin screw processor has first and second conveying elements, with a mixing element in between the conveying elements, and the second conveying element has at least one pitch less than at least one pitch of the first conveying element. The system also permits the optimization of a number of other design parameters, such as a location and feed rate of a side stuffer and a liquid feeder, the rotational speed of the granulator itself, and the final granulation size. The system is particularly suitable for producing a granulation of nelfinavir mesylate along with excipients, including calcium silicate, for a high dose product.